Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Total Assets : $3.59 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lixte Biotechnology Holdings Total Assets?

Lixte Biotechnology Holdings's Total Assets for the quarter that ended in Mar. 2024 was $3.59 Mil.

During the past 12 months, Lixte Biotechnology Holdings's average Total Assets Growth Rate was -28.00% per year. During the past 3 years, the average Total Assets Growth Rate was -12.60% per year. During the past 5 years, the average Total Assets Growth Rate was 19.40% per year. During the past 10 years, the average Total Assets Growth Rate was -1.70% per year.

During the past 13 years, Lixte Biotechnology Holdings's highest 3-Year average Total Assets Growth Rate was 247.60%. The lowest was -48.50%. And the median was 28.65%.

Total Assets is connected with ROA %. Lixte Biotechnology Holdings's annualized ROA % for the quarter that ended in Mar. 2024 was -98.35%. Total Assets is also linked to Revenue through Asset Turnover. Lixte Biotechnology Holdings's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Lixte Biotechnology Holdings Total Assets Historical Data

The historical data trend for Lixte Biotechnology Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Total Assets Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

2.67

5.23

5.09

5.56

4.31

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															4.33	3.10	5.24	4.31	3.59

Lixte Biotechnology Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Lixte Biotechnology Holdings's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	3.995	+	0.314
	=	4.31

Lixte Biotechnology Holdings's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	3.126	+	0.463
	=	3.59

Lixte Biotechnology Holdings (NAS:LIXTW) Total Assets Explanation

Total Assets is connected with ROA %.

Lixte Biotechnology Holdings's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-3.884	/	( (4.309	+	3.589)	/ 2 )
	=	-3.884	/	3.949
	=	-98.35 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Lixte Biotechnology Holdings's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (4.309	+	3.589)	/ 2 )
=	0	/	3.949
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Lixte Biotechnology Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXTW) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.